ReviewBiochimica et biophysica acta2008
The Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevance.
Review in Biochimica et biophysica acta, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 182 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
182 citing papers in PubMed.
- Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate patients with COVID-19.Frontiers in immunology · 2024Trial
- Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacy.Cancer biology & therapy · 2013Trial
- Polysaccharide responsiveness is not biased by prior pneumococcal-conjugate vaccination.PloS one · 2013Trial
- ImmunoCAP-Based Detection of Alpha-Gal Syndrome: A Reproducible Diagnostic Protocol for Human Patients.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Anti-Alpha-Gal Antibodies Against Gangliosides: Preliminary Data on a New Autoimmune Target in Alzheimer's Disease Patients.International journal of molecular sciences · 2026Article
- The alpha-gal syndrome: Understanding the role of tick bites, and the delays in severe anaphylaxis.Allergy and asthma proceedings · 2026Review
- From vector to allergen: exploring the immunology of tick-triggered α-Gal syndrome.Frontiers in immunology · 2026Review
- The Role ofPathogens (Basel, Switzerland) · 2025Article
- The Immunology of Alpha-Gal Syndrome: History, Tick Bites, IgE, and Delayed Anaphylaxis to Mammalian Meat.Immunological reviews · 2025Review
- Molecular Tweezers for Biomimetic Recognition of Carbohydrates.Chembiochem : a European journal of chemical biology · 2025Review
- Highly variable aggregation and glycosylation profiles and their roles in immunogenicity to protein-based therapeutics.Journal of pharmaceutical sciences · 2025Review
- Perioperative Outcomes After Bioprosthetic Valve Replacement in Patients Sensitized to Alpha-Gal.Annals of thoracic surgery short reports · 2025Article
- Alpha-gal syndrome and the gastrointestinal reaction: a narrative review.Frontiers in allergy · 2025Review
- Single-cell mRNA analysis and surface marker expression profiling of circulating immune cells in humans with alpha-gal syndrome.Frontiers in immunology · 2025Article
- Some Human Anti-Glycan Antibodies Lack the Ability to Activate the Complement System.Antibodies (Basel, Switzerland) · 2024Article
- Non-targeted N-glycome profiling reveals multiple layers of organ-specific diversity in mice.Nature communications · 2024Article
- Probiotics: an alternative anti-parasite therapy.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2024Review
- Glycosphingolipids: from metabolism to chemoenzymatic total synthesis.Organic & biomolecular chemistry · 2024Review
- Alpha-Gal Syndrome: An Underrated Serious Disease and a Potential Future Challenge.Global challenges (Hoboken, NJ) · 2024Review
- Alpha-Gal syndrome as a novel food allergy: a case report study.Annals of medicine and surgery (2012) · 2024Article
122 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
In 1985, we reported that a naturally occurring human antibody (anti-Gal), produced as the most abundant antibody (1% of immunoglobulins) throughout the life of all individuals, recognizes a carbohydrate epitope Galalpha1-3Galbeta1-4GlcNAc-R (the alpha-gal epitope). Since that time, an extensive literature has developed on discoveries related to the alpha-gal epitope and the anti-Gal antibody, including the barrier they form in xenotransplantation and their reciprocity in mammalian evolution. This review covers these topics and new avenues of clinical importance related to this unique antigen/antibody system (alpha-gal epitope/anti-Gal) in improving the efficacy of viral vaccines and in immunotherapy against cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.